D. Boral Capital Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) had its price objective increased by D. Boral Capital from $2.00 to $3.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the stock. Separately, HC Wainwright reissued a “buy” rating on shares of Lineage Cell Therapeutics in a research report on […]
7 Mar 11:46 · The Cerbat Gem